There are currently 112 ongoing clinical trials involving Constipation
Of the 112 trials,55 trials are in Phase II
Furthermore, 21 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Constipation, a Gastrointestinal indication. The largest number of ongoing clinical trials for Constipation is conducted in Asia-Pacific. North America and Europe are among some of the other prominent regions involved in Constipation-related drug trials.
EA Pharma Co Ltd: The leading ongoing Constipation-related clinical trial sponsor
EA Pharma Co Ltd, a Japan-based pharmaceuticals company, is the top sponsor for Constipation-related ongoing clinical trials.
The University of Nottingham, Takeda Pharmaceutical Co Ltd, The Himalaya Drug Company, Guangzhou First People's Hospital, and Enterin Inc are a few other notable sponsors involved in Constipation. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Constipation
Linaclotide (Linzess, Constella), Lubiprostone (Amitiza), and Lubiprostone (Amitiza) are among the key marketed drugs involving Constipation.
Linaclotide (Linzess, Constella) is an anti-constipation agent. It functions via the Heat Stable Enterotoxin Receptor (Guanylyl Cyclase C or Intestinal Guanylate Cyclase or GUCY2C or EC 4.6.1.2) Agonist mechanism of action. It is formulated as hard gelatin capsules and tablets for oral route of administration. Linaclotide is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support. Linaclotide was first approved in 2012 and is marketed globally including the US, the UK, France, Germany, China, and Japan by Allergan Sales LLC.
Lubiprostone (Amitiza) is a bicyclic fatty acid (prostaglandin E1 derivative) acts as anti-constipation agent. It functions via Chloride Channel Protein 2 (CLCN2) Activator mechanism of action. It is formulated as soft gelatin capsules for oral route of administration. Amitiza is indicated for the treatment of opioid-induced constipation, chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in women. Lubiprostonewas first approved in 2006 and is marketed globally including the US, the UK, Germany, and Japan by Mallinckrodt LLC.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer